/ /

Michelle Dalton, ELS
Infections with EK procedures rising
Descemet’s stripping automated endothelial keratoplasty (DSAEK) appears to have a higher risk of postoperative fungal infections (predominantly Candida) when compared to penetrating keratoplasty (PK).
Inhibition of PlGF shows additional features compared to VEGF inhibition
Anti-vascular endothelial growth factor (VEGF) remains the gold standard therapy for diabetic retinopathy, but “when treating diabetic macular edema (DME), “about half of the patients treated with VEGF inhibitors do not respond to therapy,” said Tine Van Bergen, PhD, a scientist with ThromboGenics, Leuven, Belgium.
Real-world outcomes with aflibercept better in treatment-naïve patients
After 12 months of treatment with intravitreal aflibercept injections, both treatment-naïve and pre-treated patients demonstrated visual acuity gains. Visual acuity improvement was higher in treatment-naïve patients.
Novel glaucoma drug lowers IOP by unique combination of mechanisms
In a study of normal volunteers, once-daily dosing of netarsudil mesylate ophthalmic solution 0.02% lowered IOP relative to baseline by increasing outflow facility and decreasing episcleral venous pressure.
Managing conjunctival pigmented lesions
Knowing how to recognize and manage the various forms of conjunctival pigmented lesions can literally mean the difference between life and death in some cases.
FDA approves tocilizumab, first therapy for GCA
The FDA recently granted regulatory approval for tocilizumab (Actemra, Genentech), the first approved therapy for the treatment of adults with giant cell arteritis.
Pros and cons of compounded pharmaceuticals
Compounded pharmaceuticals have been used for decades, but does that mean they are reliable and safe? “Absolutely,” asserted Dante Pieramici, MD. “The literature disagrees,” said Julia Haller, MD.
Is DSAEK still the gold standard over DMEK for endothelial disease?
Multiple advantages of DSAEK include successful outcomes, less risk of graft tears, and alternative options for complex patients with comorbidities. Overall, the procedure offers an aspect of simplicity in that it also has less restrictions for donor age criteria compared with DMEK.
Researchers find arthritis therapy ‘effective’ for noninfectious uveitis
Multiple intravenous administrations of tocilizumab for noninfectious uveitis can be effective in improving visual acuity and reducing vitreous haze.
Adalimumab promising in treating JIA-associated uveitis, study finds
Results from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.